To further clarify whether the AKT/GSK3β/β-catenin pathway regulated the ACTN1 overexpression-induced migration abilities of GC, we treated GC cell lines overexpressing ACTN1 with 10 μL of MK2206 (an AKT inhibitor). The gene discussed is AKT1; the disease is gastric cancer.